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Hepatocellular carcinoma (HCC) remains one of the deadliest human carcinomas, with more than 40,000 diagnoses and 25,000 deaths each year in the United States alone.[1](#hep41422-bib-0001){ref-type="ref"}, [2](#hep41422-bib-0002){ref-type="ref"} At advanced stages of HCC, systemic therapies improve clinical outcomes, although the median overall survival remains a little more than 1 year.[2](#hep41422-bib-0002){ref-type="ref"}, [3](#hep41422-bib-0003){ref-type="ref"} It is therefore necessary to better understand the molecular pathways involved in HCC development and invasion in order to find novel strategies to treat such tumors. Moreover, chemotherapy, radiation, and surgery have limited effects in the treatment of HCC. More than a third of human HCCs exhibit gene expression profiles consistent with Wnt signaling activation, with cadherin‐associated protein beta 1 (*CTNNB1*)‐activating mutations occurring in approximately one third of these cases.[2](#hep41422-bib-0002){ref-type="ref"}, [3](#hep41422-bib-0003){ref-type="ref"} However, multiple strategies targeting β‐catenin in the Wnt pathway have had limited success in clinical trials[2](#hep41422-bib-0002){ref-type="ref"} because of toxicity caused by systemic off‐target effects.[4](#hep41422-bib-0004){ref-type="ref"}, [5](#hep41422-bib-0005){ref-type="ref"} It remains possible that some alterations in Wnt pathway regulators are better drug targets as well as other downstream Wnt effectors.[6](#hep41422-bib-0006){ref-type="ref"}

R‐spondins (RSPOs) are secreted proteins that bind leucine‐rich repeat‐containing G‐protein‐coupled receptor (LGR) 4/5/6 transmembrane receptors and enhance Wnt signaling by means of Frizzled receptors.[7](#hep41422-bib-0007){ref-type="ref"} Sustained Wnt signaling by RSPO/LGR interaction is through inhibition of a negative feedback loop by causing membrane clearance of zinc and ring finger 3 (ZNRF3), resulting in enhanced Wnt signaling.[8](#hep41422-bib-0008){ref-type="ref"}, [9](#hep41422-bib-0009){ref-type="ref"}, [10](#hep41422-bib-0010){ref-type="ref"} Recurrent rearrangements that result in *RSPO2* and *RSPO3* overexpression were identified in 4% to 10% of human colorectal cancer (CRC) cases, mutually exclusive of adenomatous polyposis coli (*APC*) mutations.[11](#hep41422-bib-0011){ref-type="ref"}, [12](#hep41422-bib-0012){ref-type="ref"} Sleeping Beauty transposon‐based insertional mutagenesis screens performed in *APC* wild‐type mice identified *Rspo2* as a common insertion site in gastrointestinal tumors, and *Rspo2* and *Rspo3* are common insertions sites in mouse mammary tumor virus‐driven breast cancer models.[13](#hep41422-bib-0013){ref-type="ref"}, [14](#hep41422-bib-0014){ref-type="ref"}, [15](#hep41422-bib-0015){ref-type="ref"}, [16](#hep41422-bib-0016){ref-type="ref"}, [17](#hep41422-bib-0017){ref-type="ref"}, [18](#hep41422-bib-0018){ref-type="ref"} Targeting RSPO2 can inhibit cancer by promoting differentiation, which reduces proliferation and stemness.[19](#hep41422-bib-0019){ref-type="ref"}, [20](#hep41422-bib-0020){ref-type="ref"}, [21](#hep41422-bib-0021){ref-type="ref"} These studies support the hypothesis that RSPOs act as oncogenes that activate canonical Wnt signaling. On the other hand, recent studies have shown interactions between the Wnt and Hippo signaling pathways because the yes‐associated protein (YAP) can be a substrate for the APC destruction complex.[22](#hep41422-bib-0022){ref-type="ref"} The Hippo/YAP pathway has also been shown to be necessary for liver regeneration and control of organ size and hepatocyte differentiation, leading to HCC regression.[23](#hep41422-bib-0023){ref-type="ref"}, [24](#hep41422-bib-0024){ref-type="ref"} The Hippo pathway\'s main effector, the YAP/tafazzin (TAZ) complex, promotes proliferation and inhibits apoptosis when translocated to the nucleus, where it acts as a transcriptional coactivator.[22](#hep41422-bib-0022){ref-type="ref"} Because of these molecular interactions and Hippo/Yap physiological functions in the liver, we hypothesized that RSPO2 activates both Wnt/β‐catenin and Hippo/Yap signaling pathways and that YAP is necessary for development of RSPO2‐driven HCC.

In this study, we provide *in vitro* and *in vivo* models of RSPO2‐driven HCC/hepatocyte transformation and show strong dual canonical Wnt and Hippo pathway activation. We show that *RSPO2* is overexpressed in a subset of human HCC, it activates the Wnt and Hippo pathways, and abrogation of YAP inhibits RSPO2‐driven liver tumor formation. Both RSPO2 and YAP1 represent potential druggable targets against a subset of HCCs, opening a new avenue to treating some cancers characterized by activation of Wnt/β‐catenin signaling.

Materials and Methods {#hep41422-sec-0002}
=====================

Acquisition of RNA Sequencing and Somatic Mutation Data from the Cancer Genome Atlas {#hep41422-sec-0003}
------------------------------------------------------------------------------------

RNA sequencing (RNA‐seq) and somatic mutation data were extracted from The Cancer Genome Atlas (TCGA) data matrix. RNA‐seq normalized counts were obtained for a set of 69 genes of interest related to RSPOs, Wnt signaling, and tissue‐specific markers of differentiation and stemness for 50 normal livers and 200 with HCC. Somatic mutation data were obtained for *APC, CTNNB1, RSPO1, RSPO2, RSPO3*, and *RSPO4* from 200 HCC livers.

Primary Liver Tissues and Microarray Gene Expression Analysis {#hep41422-sec-0004}
-------------------------------------------------------------

Gene expression profiling of 319 primary HCC samples, 199 cirrhotic or premalignant samples, and 23 normal liver samples were analyzed for this study. HCC samples were classified according to described subtypes.[25](#hep41422-bib-0025){ref-type="ref"} Five gene expression classes were defined by hierarchical clustering for a training set of HCCs. Marker genes were identified that were differentially expressed in each class (CTNNB1, interferon, proliferation, polysomy of chromosome 7, and unannotated). Expression of marker genes was used to classify subsequent HCC samples.

Tissue Culture Reagents and Cell Lines {#hep41422-sec-0005}
--------------------------------------

The human hepatocyte (HH)7 cell line was kindly donated.[26](#hep41422-bib-0026){ref-type="ref"} HH7 cells were cultured in Dulbecco\'s modified Eagle\'s medium supplemented with 10% fetal bovine serum, 5% nonessential amino acids, glutamine, and 1% penicillin/streptomycin. All cells were grown on tissue culture‐treated plates at 37°C and 5% CO~2~.

*In Vitro* Gene Knockdown and Overexpression and Proliferation Assays {#hep41422-sec-0006}
---------------------------------------------------------------------

For overexpression experiments, lentiviral expression vectors were cloned with RSPO2 or *Discosoma* sp. red fluorescent protein (DsRed) regulated by an AAV Blank Control Vector promoter and followed by an internal ribosome entry site‐red fluorescent protein (RFP) to monitor transduction efficiency. Lentiviral particles were produced in 293T cells by cotransfection with helper plasmids. For both knockdown and overexpression experiments, viral supernatant was collected after 24 hours of virus production, cleared, and applied to transduce experimental cells with 12 μg/mL polybrene overnight. Transduced cells were selected with 1 μg/mL puromycin. Knockdown efficiency and overexpression levels were assayed by quantitative reverse‐transcriptase polymerase chain reaction (qRT‐PCR).

Mouse Strains, Hydrodynamic Injection, and Liver Analysis {#hep41422-sec-0007}
---------------------------------------------------------

All animal work was conducted according to an institutionally approved animal welfare protocol. Mouse strains and hydrodynamic injection protocols were as described.[27](#hep41422-bib-0027){ref-type="ref"}, [28](#hep41422-bib-0028){ref-type="ref"} Briefly, doubly transgenic mice (fumarylacetoacetate hydrolase \[*Fah\]^−/−^; Rosa26‐SB11*) received 20 μg plasmid DNA per plasmid by hydrodynamic tail vein injection. Plasmid DNA encoded transposon‐based sequences expressing (1) *Fah*, green fluorescent protein (GFP), luciferase, and either *RSPO2, CTNNB1‐S33Y,* or GFP control; and (2) transformation‐related protein 53 (*Trp53*) short hairpin RNA (shRNA), *shYap1* shRNA, or no plasmid control. Experimental cohort details are listed in Supporting Table [S2](#hep41422-sup-0008){ref-type="supplementary-material"}. Construct *shYap1* was selected based on knockdown efficiency *in vitro*, as depicted in Supporting Fig. [S6](#hep41422-sup-0006){ref-type="supplementary-material"}. Mice were maintained on 2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione (NTBC)‐supplemented drinking water until after injections. At the indicated time points, mice were euthanized, and lungs, hearts, spleens, pancreases, livers, and all abnormal tissues were removed and visually inspected for macroscopic tumors. Macroscopic hyperplastic nodules were counted. Nodules at least 1 mm in size were isolated and snap frozen for RNA extraction. Larger nodules were fixed in 10% formalin, paraffin‐embedded, mounted, and sectioned at 5 µm. Slides were processed and stained with hematoxylin and eosin. Brightfield images of hepatic parenchyma were obtained using an Olympus BX45 microscope equipped with an Olympus DP70 camera and analyzed by two board‐certified pathologists (K.A. and M.L., American Board of Pathology). A reticulin stain was performed on select blocks using a Leica automated stainer. Immunohistochemistry (IHC) for CTNNB1 was performed using β‐catenin (6B3) rabbit monoclonal antibody (mAb) (\#9582; Cell Signaling Technology) at 1:100.[29](#hep41422-bib-0029){ref-type="ref"} CTNNB1 localization and intensity were scored by two independent blinded reviewers (C.C. and B.T.). YAP staining was performed in the same way (H.H. and G.K.) using YAP (D8H1X) rabbit mAb (\#1074; Cell Signaling) at 1:400.

qRT‐PCR {#hep41422-sec-0008}
-------

RNA was isolated from cell lines and mouse liver tissues using the PureLink RNA Mini Kit (Ambion). RNA samples were analyzed by gel electrophoresis to assess quality and treated with deoxyribonuclease to remove contaminating genomic DNA (Turbo DNA‐free Kit; Ambion). Complementary DNA (cDNA) was synthesized from 1 μg template RNA per sample using random hexamer primers (SuperScript III First‐Strand Synthesis System; Invitrogen). qRT‐PCR reactions were conducted with FastStart Universal SYBR Green Master Mix (Roche) using 0.5 μL cDNA template per 25 μL reaction. Primer sequences for qRT‐PCR reactions are listed in Supporting Table [S3](#hep41422-sup-0009){ref-type="supplementary-material"}. Data were normalized to actin beta (ACTB) using the following equation: relative expression = 2^CT_ACTB^/2^CT_GOI^.

Oncogenic Potential *In Vitro* Studies of *RSPO2* in HH7 Cells {#hep41422-sec-0009}
--------------------------------------------------------------

Soft‐agar assays were performed using 0.48% low melting point agarose in sterile water. A total of 7,500 cells were plated per well in a six‐well plate. Pictures were taken in a dissecting microscope at 1.5× and analyzed using ImageJ. Xenograft models were performed in nonobese diabetic/recombination activating gene (*NRG*) mice, and 3 million cells were injected subcutaneously in media containing Matrigel (1:1). Tumors were harvested 4 months after injection. Cells were lysed with a hypotonic solution, and nuclear fractions were isolated using Nonidet P40 followed by centrifugation. Pellets were resuspended in radio immunoprecipitation assay buffer supplemented with protease and phosphatase inhibitors.

CRISPR/Cas9 Knockout of *Yap1* {#hep41422-sec-0010}
------------------------------

Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR‐associated protein 9 (Cas9) HH7‐*RSPO2 Yap1* modified cell lines were generated using lentiviral vectors expressing Cas9 and a guide RNA (gRNA) directed against *Yap1*. Lentiviral vectors were generated by transfecting 293T cells with two viral packaging plasmids and CC9 v2 Cas9/gRNA‐containing plasmid from the Zhang Lab at the Massachusetts Institute of Technology (<https://zlab.bio/guide-design-resources>). gRNA sequences were cloned into a stuffer region of the plasmid using BsmB1 restriction sites. gRNA sequences were 5′‐GGCGTAGCCCTCGCTCGC‐3′ and 5′‐CGGCGCTGTCCTCGCTCT‐3′ and targeted the translational start site.

Results {#hep41422-sec-0011}
=======

*RSPO2* is Up‐Regulated in Human Liver Cancer and is Associated with an Activated Wnt Signaling Gene Expression Profile {#hep41422-sec-0012}
-----------------------------------------------------------------------------------------------------------------------

To characterize the role of RSPOs in HCC, we first analyzed *RSPO2*/*3* messenger RNA (mRNA) levels and gene copy number variation (CNV) in two HCC cohorts (training and validation), including 255 HCC, 31 adjacent cirrhotic tissue, and 10 normal liver samples. Microarray analysis displayed uniformly low *RSPO2* mRNA levels in normal and cirrhotic livers but significantly higher *RSPO2* levels in the molecular class of HCC characterized by activated Wnt signaling and *CTNNB1* mutations[30](#hep41422-bib-0030){ref-type="ref"} (*P* \< 0.01; Fig. [1](#hep41422-fig-0001){ref-type="fig"}A,B; Supporting Fig. [S1](#hep41422-sup-0001){ref-type="supplementary-material"}C). In addition, chromosomal high‐level amplifications (\[cHLAs\]; defined as copy number gains \>3.8) involving *RSPO2* were identified in 8% of the tumor samples but not seen in adjacent cirrhotic/nontumor tissues (*P* \< 0.001; Fig. [1](#hep41422-fig-0001){ref-type="fig"}C). *RPSO2* cHLAs were significantly enriched in the CTNNB1 class of HCC (*P* \< 0.001; Fig. [1](#hep41422-fig-0001){ref-type="fig"}D,E). However, *RSPO2* mRNA level and gene copy number were not significantly correlated (Spearman *r* = 0.10), suggesting that overexpression of RSPO2 is not entirely driven by CNVs.

![RSPO2 is up‐regulated in HCC and associated with Wnt signaling activation. (A) *RSPO2* mRNA levels in normal liver, adjacent nontumor/cirrhotic liver, and HCC tumor samples (training cohort; n = 134). Box plots display percentiles 5% to 95%, with 50th percentile lines. (B) *RSPO2* mRNA levels in nontumor/Ci liver and HCC grouped by molecular subclass, as defined in a previous study.[25](#hep41422-bib-0025){ref-type="ref"} (C) Estimated *RSPO2* gene copy number in HCC and adjacent nontumor/Ci liver. (D) Estimated *RSPO2* gene copy number in HCC by molecular subclass; \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. (E) Wnt target gene mRNA levels in nontumor/Ci liver versus HCC with low and high RSPO2 levels in the training cohort. Abbreviations: Ci, cirrhotic; NS, not significant.](HEP4-3-1496-g001){#hep41422-fig-0001}

Next, we assessed expression of Wnt target genes and enrichment of Wnt signatures in HCC. Tumors that expressed high levels of *RSPO2* had significantly elevated expression of Wnt target genes (axis inhibitor protein 2 \[*AXIN2*\], lymphoid enhancer factor 1 \[LEF1\], T‐cell factor 7 \[*TCF7*\], and *LGR5*) compared to normal liver or tumors with low *RSPO2* levels (Fig. [1](#hep41422-fig-0001){ref-type="fig"}E). Moreover, gene set enrichment analysis showed that Wnt‐related signatures were significantly enriched in samples with increased copy number of *RSPO2,* similar to samples with *CTNNB1* mutation (false discovery rate *q* value, \<25%; Supporting Table [S1](#hep41422-sup-0007){ref-type="supplementary-material"}). Indeed, *CTNNB1* mutation was associated with increased *RSPO2* mRNA expression and copy number, indicating these events tended to co‐occur (Supporting Fig. [S1](#hep41422-sup-0001){ref-type="supplementary-material"}E).

*RSPO3* mRNA levels were decreased in HCC overall and in all subclasses compared to normal, cirrhotic, or premalignant samples (*P* \< 0.001; Supporting Fig. [S1](#hep41422-sup-0001){ref-type="supplementary-material"}A). Low *RSPO3* transcript levels were accompanied by *RSPO3* gene copy number losses, which were identified in 25% of the tumors but absent in the nontumor tissue (*P* \< 0.001; Fig. [1](#hep41422-fig-0001){ref-type="fig"}E; Supporting Fig. [S1](#hep41422-sup-0001){ref-type="supplementary-material"}B).

These findings were confirmed by analysis of gene expression data from an additional 200 liver tumors and 50 normal liver samples (TCGA data set). *RSPO2* was overexpressed in HCC overall, with 12% of samples having more than 4‐fold increased *RSPO2* mRNA level compared to normal liver (Supporting Fig. [S2](#hep41422-sup-0002){ref-type="supplementary-material"}C). RSPO2‐high status was associated with *CTNNB1* mutation (*P* = 1.72E‐09) and elevated expression of Wnt target genes (*AXIN2, TCF7, LEF1, LGR5*; Supporting Fig. [S2](#hep41422-sup-0002){ref-type="supplementary-material"}A,B). *RSPO3* mRNA expression was suppressed in HCCs overall, and only one sample (0.5%) was identified as RSPO3 high (Supporting Figs. [S2](#hep41422-sup-0002){ref-type="supplementary-material"}A and [S6](#hep41422-sup-0002){ref-type="supplementary-material"}).

Regarding the mechanism of *RSPO2* overexpression, deFuse analysis of RSPO‐high liver tumors in the TCGA set did not identify expression of *RSPO2* or *RSPO3* gene fusions. Further, in a murine model of HCC driven by activating a mutation of β‐catenin (CTNNB1‐S33Y), *Rspo2* was not overexpressed (Supporting Fig. [S3](#hep41422-sup-0003){ref-type="supplementary-material"}). These results suggest that, although high RSPO2 expression co‐occurs with CTNNB1 mutation in liver cancer, elevated RSPO2 expression is not merely a consequence of Wnt signaling activated by CTNNB1 but rather an independently selected event.

*RSPO2* Promotes Wnt Signaling and Tumorigenesis in the Mouse Liver {#hep41422-sec-0013}
-------------------------------------------------------------------

To study the role of elevated *RSPO2* expression in liver cancer, we next generated mice that somatically expressed *RSPO2*, alone or with knockdown of *Trp53*, by hydrodynamic injection and *Fah* selection. The *Fah* mouse model lacks the Fah gene product*,* the last step in the metabolism of tyrosine. These mice accumulate hepatotoxic metabolites. The mice are maintained with NTBC, a hepatoprotective drug that inhibits tyrosine metabolism upstream of Fah. This model takes advantage of this by rescuing *Fah*, along with our gene of interest, effectively repopulating the mouse liver with humanized hepatocytes. Control mice were injected with a transposon vector expressing *Fah*, GFP, and luciferase to track liver repopulation. Experimental mice were injected with a transposon vector expressing *Fah*, GFP, luciferase, and *RSPO2*, and additional GFP and RSPO2 cohorts were injected with a second transposon vector expressing *Trp53* shRNA (Fig. [2](#hep41422-fig-0002){ref-type="fig"}A). Necropsies were performed to assess liver mass and tumor formation and analyzed at the molecular level. Hepatic expression of GFP was confirmed at necropsy by visualization with GFP goggles. At early time points (day 15 to 25 after hydrodynamic injection of peptide histidine isoleucine \[PHI\]), mice injected with *RSPO2* had slightly enlarged livers compared to GFP controls (1.2‐fold to 1.5‐fold; *P* \> 0.05). At later time points, there was a prominent phenotype of enlarged liver (hepatomegaly) in mice injected with *RSPO2* with or without *Trp53* shRNA compared to GFP controls (1.6‐fold to 2.2‐fold enlarged; *P* \< 0.01), whereas mice injected with *Trp53* shRNA alone did not develop enlarged livers (Fig. [2](#hep41422-fig-0002){ref-type="fig"}B,C). To characterize the enlarged liver phenotype, sections of grossly normal liver were stained with 4ʹ,6‐diamidino‐2‐phenylindole to quantify nuclear density. Mice injected with *RSPO2* or *RSPO2* and *Trp53* shRNA had 30% to 40% increased nuclear density compared to control mice receiving GFP or GFP and *Trp53* shRNA, suggesting enlarged livers in these mice arose due to hyperplastic growth (Fig. [2](#hep41422-fig-0002){ref-type="fig"}D,E).

![RSPO2 expression drives hyperplastic growth in the mouse liver. (A) Experimental diagram. (B) Average liver mass was significantly increased in mice injected with RSPO2 alone or in combination with Trp53 shRNA (shp53) compared to GFP or GFP/shp53 control mice at all time points 60 to 150 days PHI; \**P* \< 0.05. (C) Representative necropsy images illustrating hepatomegaly of mice injected with *RSPO2*. (D) Sections of grossly normal liver from mice at 150 days after hydrodynamic injection were stained with DAPI to visualize nuclear density at 40× magnification. (E) Nuclei per 40× field were quantified for six livers per group. Nuclear density increased 30% to 40% with RSPO2 expression, consistent with hyperplastic growth. Bars show mean + SD. \**P* \< 0.05, \*\**P* \< 0.01. Abbreviations: DAPI, 4ʹ,6‐diamidino‐2‐phenylindole; Luc, luciferase.](HEP4-3-1496-g002){#hep41422-fig-0002}

At 150 days PHI, mice injected with GFP or GFP and *Trp53* shRNA had low tumor penetrance (4%‐5%), consistent with the background level of tumor formation in this model (Fig. [3](#hep41422-fig-0003){ref-type="fig"}A). Mice injected with *RSPO2* alone had a nonsignificant increase in tumor penetrance (18%). However, expression of *RSPO2* combined with *Trp53* shRNA dramatically increased tumor penetrance (63% of *RSPO2/Trp53* shRNA mice vs. 5.2% of GFP/*Trp53* shRNA mice; *P* = 3.37E‐5; Fig. [3](#hep41422-fig-0003){ref-type="fig"}A). *RSPO2/Trp53* shRNA‐injected mice formed 1.8 tumors/mouse on average (range, 1‐5). Histologic examination determined the tumors were HCCs with areas of necrosis and lymphocytic infiltration (Fig. [3](#hep41422-fig-0003){ref-type="fig"}B,C).

![RSPO2 promotes tumor formation in the mouse liver. (A) Tumor penetrance in *Fah*‐null mice injected with GFP (18 animals), *RSPO2* (19 animals), GFP plus shRNA against *Trp53* (GFP/*shp53*) (20 animals), or *RSPO2* plus shRNA against *Trp53* (*RSPO2*/*shp53*) (19 animals) at 150 days PHI (*P* = 3.37E‐5). (B) Gross images of representative livers from *RSPO2*/*shp53*‐injected mice at 150 days PHI. Tumors are indicated by green arrowheads; scale bar, 1 cm. (C) Representative hematoxylin and eosin‐stained sections of *RSPO2*/*shp53*‐injected mouse liver and tumor. Upper left, low‐power view of liver nodule; magnification ×2. Upper middle, hepatocellular carcinoma with lymphoid infiltrate and necrosis; magnification ×10. Upper right, dysplastic liver parenchyma; magnification ×10. Lower left, high‐power view of dysplastic liver parenchyma; magnification ×50. Lower middle, hepatocellular carcinoma with clear cell change, indicated by black arrowheads; magnification ×50. Lower right, high‐power view of hepatocellular carcinoma with mitotic figures, indicated by black arrows; magnification ×50. Scale bars, 100 μm. Abbreviations; L, liver; N, necrosis; T, tumor.](HEP4-3-1496-g003){#hep41422-fig-0003}

Expression of *RSPO2* and its effect on Wnt signaling were assessed by qRT‐PCR and IHC. Expression of *RSPO2* alone compared to GFP‐injected controls increased expression of Wnt target genes (*Axin2, Tcf7,* and *Lgr5*) at early time points (days 15‐25 PHI) (Supporting Fig. [S4](#hep41422-sup-0004){ref-type="supplementary-material"}). At day 150 PHI, expression of Wnt target genes and nuclear localization of CTNNB1 were significantly increased in both livers and tumors from mice injected with *RSPO2* and *Trp53* compared to GFP/*Trp53* shRNA‐injected controls (Fig. [4](#hep41422-fig-0004){ref-type="fig"}A‐C). These data confirm that RSPO2 expression enhances Wnt/β‐catenin signaling and promotes HCC formation in the mouse liver.

![RSPO2 increases Wnt signaling in the mouse liver. (A,B) Expression of (A) *RSPO2* and (B) endogenous Wnt target genes were assessed by qRT‐PCR in grossly normal liver and tumor samples from mice injected with GFP/Trp53 shRNA or RSPO2/Trp53 shRNA. Wnt target genes were significantly elevated in murine liver and tumors expressing RSPO2. Data points represent gene expression value per animal. Lines represent the mean. (C) β‐catenin protein expression and localization were examined by IHC staining in normal liver and tumor samples from mice injected with GFP/*Trp53* shRNA or *RSPO2/Trp53* shRNA. Cytoplasmic and nuclear expressions of β‐catenin were elevated in tumors from *RSPO2/shp53*‐injected mice. Bars represent mean + SD; \**P* \< 0.05.](HEP4-3-1496-g004){#hep41422-fig-0004}

The Hippo/YAP Pathway is Activated Following *RSPO2* Signaling in the Mouse Liver {#hep41422-sec-0014}
---------------------------------------------------------------------------------

Recent studies have shown the Hippo pathway interacts with Wnt signaling by Yap binding to the β‐catenin destruction complex and that it is required for CRC cell survival.[21](#hep41422-bib-0021){ref-type="ref"}, [22](#hep41422-bib-0022){ref-type="ref"} Based on the pronounced phenotype of hepatomegaly in liver overexpressing RSPO2, we tested the effect of *RSPO2* overexpression on Yap nuclear localization as a measurement of Hippo activation. We stained liver tissue and scored each section for Yap nuclear and cytoplasmic localization. We assessed Yap staining qualitatively and scored each field of view using 0 (no staining), 1 (low), 2 (medium), and 3 (high) (Fig. [5](#hep41422-fig-0005){ref-type="fig"}A). We found that, following *RSPO2* overexpression, Yap nuclear localization and overall levels were increased (Fig. [5](#hep41422-fig-0005){ref-type="fig"}B). Further, RNA was isolated from normal and tumor liver tissue from the *Fah/RSPO2/shp53* mice described above and quantified by qRT‐PCR. We found *RSPO2* overexpression in the mouse liver results in overexpression of the Yap target gene B‐cell lymphoma‐2‐like protein 1 (*Bcl2l1*) in RSPO2‐high and tumor tissue (Fig. [5](#hep41422-fig-0005){ref-type="fig"}C). On the other hand, we saw a significant overexpression of the Yap target gene baculovirus inhibitor of apoptosis protein repeat containing 5 (*Birc5*) in *RSPO2* tumor tissue (Fig. [5](#hep41422-fig-0005){ref-type="fig"}D).

![RSPO2 overexpression in the mouse liver results in Hippo signaling activation. *RPSO2* overexpression in the *Fah* mouse model results in an increased expression of the Hippo/Yap target genes. (A) Mouse liver sections stained for Yap. Bottom panels show increased levels of expression and nuclear translocation in *RSPO2* overexpression livers. Scale bars, 100 μm. (B) Quantification of (A) based on IHC scoring described in the text; each data point represents an individual animal. (C) *Bcl2l1.* (D) *Birc5*. Black lines represent SD and \**P* \< 0.05. Abbreviation: NS, not significant.](HEP4-3-1496-g005){#hep41422-fig-0005}

Knockdown of *Yap1* Inhibits RSPO2‐Induced Tumor Formation in Mouse Liver {#hep41422-sec-0015}
-------------------------------------------------------------------------

In order to determine if RSPO2‐driven liver tumors depend on YAP for development and maintenance, we hydrodynamically injected an expression vector encoding an shRNA versus *Yap1* in the presence or absence of RSPO2 and/or shTrp53. Control mice were injected with a transposon vector expressing *Fah*, GFP, and luciferase to track liver repopulation. Experimental mice were injected with a transposon vector expressing *Fah*, GFP, luciferase, and *RSPO2*, and additional GFP and RSPO2 cohorts were injected with a second transposon vector expressing *Trp53* shRNA, all containing a second and/or third vector expressing an shRNA against *Yap1* (Fig. [6](#hep41422-fig-0006){ref-type="fig"}A). Necropsies were performed to assess tumor formation 150 days PHI. *Yap1* knockdown led to a dramatic decrease in tumor penetrance, suggesting a direct role of *Yap1* in RSPO2‐mediated tumorigenesis. Only one of nine (11%) experimental animals hydrodynamically injected with *RPSO2*, *shTrp53*, and *shYap1* expression vectors formed tumors, whereas RSPO2/shp53‐injected mice again had 68% tumor penetrance (Fig. [6](#hep41422-fig-0006){ref-type="fig"}D,E). *Yap1* knockdown was confirmed by IHC (Fig. [6](#hep41422-fig-0006){ref-type="fig"}B,C), with both cytoplasmic and nuclear stains showing reduced staining for Yap when the shRNA vectors were co‐injected.

![Loss of Yap1 results in decreased RSPO2‐driven tumor formation. (A) Experimental diagram. (B) IHC showing *in vivo* knockdown of *Yap1* in the mouse liver. Scale bars, 100 μm. (C) Quantification of (B). Bar represents the mean of each cohort. (D) Tumor penetrance in *Fah*‐null mice injected with GFP/*shYap1* (10 animals), *RSPO2/shp53/shYap1* (9 animals), or *RSPO2*/*shp53* (19 animals) at 150 days PHI (*P* \< 0.05). Bars represent percent of animals that show tumor formation. (E) Two nodules were found in the *RSPO2/shp53/shYap1.* Only one animal showed tumor penetrance. Abbreviation: Luc, luciferase.](HEP4-3-1496-g006){#hep41422-fig-0006}

*RSPO2* Overexpression in Immortalized HHs Results in Anchorage‐Independent Growth and Xenograft Tumor Formation {#hep41422-sec-0016}
----------------------------------------------------------------------------------------------------------------

Next, we overexpressed *RSPO2* in HH7 cells.[26](#hep41422-bib-0026){ref-type="ref"} We first evaluated the effects of *RSPO2* overexpression in YAP nuclear localization in HHs. We observed in a western blot that levels of total and nuclear YAP protein were increased, accompanied by levels of β‐catenin in RSPO2‐high HH7 cells and posttranslational stabilization of YAP and β‐catenin in both cytoplasmic and whole‐cell fractions (Fig. [7](#hep41422-fig-0007){ref-type="fig"}A). We tested the oncogenic effects of RSPO2 in HH7 cells by measuring growth in soft agar and tumor size in xenografts in *NRG* mice. We found *RSPO2* overexpression led to cellular transformation, including both anchorage‐independent growth and tumor formation in contrast to an RFP control (Fig. [7](#hep41422-fig-0007){ref-type="fig"}B‐D). These effects were abrogated by a gRNA targeting *YAP1.*

![Ectopic expression of *RSPO2* in HH7 cells was protumorigenic. (A) Western blots for YAP using nuclear, cytoplasmic, and whole‐cell lysates from control‐HH7 (RFP) cells and two replicates of RSPO2‐HH7 cells. Bands below YAP are nonspecific. (B) RSPO2 overexpression caused anchorage‐independent growth in soft agar. (C) Quantification of (B). Bars show mean + SD. (D) Tumors formed in the *NRG* xenograft model of RSPO2‐HH7 cells injected subcutaneously.](HEP4-3-1496-g007){#hep41422-fig-0007}

Discussion {#hep41422-sec-0017}
==========

RSPO2 has been described as an oncogene in CRC, and new therapeutic approaches are currently being tested. In fact, clinical trials have been developed using porcupine inhibitors to treat RSPO‐driven metastatic colorectal adenocarcinomas.[25](#hep41422-bib-0025){ref-type="ref"} Here, we describe an oncogenic role for RSPO2 in the liver, acting by means of both the Wnt/β‐catenin and Hippo/Yap pathways. Moreover, we show that YAP is necessary for RSPO2‐driven hepatocyte cell transformation *in vitro* and a downstream effector *in vivo*. This discovery uncovers an additional downstream mechanism that results in the survival of RSPO2‐high--CTNNB1 subtype HCC and implicates the Hippo/YAP pathway as a potential drug target in these HCCs.

Most human liver cancers maintain a low level of RSPO2, with a small subset having significantly elevated levels. These *RSPO2*‐high tumors are mainly found in the CTNNB1 subtype of HCC, as defined by Chiang et al.[25](#hep41422-bib-0025){ref-type="ref"} Wnt target genes are significantly up‐regulated in these *RSPO2*‐high liver cancers. The mechanism of *RSPO2* overexpression remains an open question. Although *RSPO2* overexpression co‐occurred with activating mutation of β‐catenin in human liver cancer, our murine model of HCC initiated by activated β‐catenin suggests these are independently selected events. Further, we were not able to detect gene fusions in *RSPO2*‐high liver cancers, as previously characterized in CRC.[11](#hep41422-bib-0011){ref-type="ref"} Chromosomal amplifications were detected at the *RSPO2* locus in 8% of tumors; however, there was not a significant correlation with mRNA levels. Loss of function of a border element, such as by CCCTC‐binding factor (CTCF) mutation or DNA hypermethylation, could also be an epigenetic mechanism that results in the ectopic overexpression of *RSPO2*. We hypothesize that elevated *RSPO2* expression is independent of activated Wnt/CTNNB1 signaling.

Using our *in vivo* liver cancer mouse model, we were able to directly test the role of RSPO2 in tumorigenesis. We found ectopic overexpression of *RSPO2* with loss of *Trp53* led to more tumors in mice compared to loss of *Trp53* alone. The resulting tumors had elevated levels of *RSPO2* and Wnt target genes as well as increased levels of nuclear and cytoplasmic Ctnnb1. These findings further indicate RSPO2 functions as an oncogene in liver cancer.[29](#hep41422-bib-0029){ref-type="ref"}

Several groups have reported that Wnt and Hippo signaling pathways interact.[22](#hep41422-bib-0022){ref-type="ref"}, [31](#hep41422-bib-0031){ref-type="ref"} We found RSPO2 overexpression led to accumulation of cytoplasmic and nuclear Yap in the mouse liver. Yap target genes involved in the regulations of apoptosis, *Bcl2l1,* and *Birc5*, were up‐regulated in some RSPO2‐driven liver tumors. Hippo/YAP activation mechanisms are varied. As demonstrated by Azollin and colleagues,[31](#hep41422-bib-0031){ref-type="ref"} we hypothesize that Hippo signaling occurs by means of a Wnt activation mechanism and that, in the case of activating mutations in *CTNNB1*, Hippo signaling is enhanced by further inactivation of APC, stabilizing YAP posttranslationally. We also demonstrated YAP activation downstream of RSPO2 in immortalized HHs and found that ectopic *RSPO2* expression led to anchorage‐independent growth and tumor formation in *NRG* mice. Interestingly, these transformation events were abrogated after the loss of *YAP1*.

Moreover, we have shown that knockdown of Yap1 in the mouse liver results in direct abrogation of RSPO2‐driven tumor development and maintenance. This finding opens new routes for the development of therapies against RSPO2‐driven cancer. The Hippo/Yap pathway is activated following lower density/size in the liver, and its inhibition has been shown to restore hepatocyte differentiations in HCC.[23](#hep41422-bib-0023){ref-type="ref"}, [24](#hep41422-bib-0024){ref-type="ref"} Activation of the pathway gives rise to cell proliferation and survival. Although Yap1 is necessary for liver regeneration and regulation of organ size,[23](#hep41422-bib-0023){ref-type="ref"} we demonstrate that Yap1 is stabilized at the posttranscriptional level following RSPO2 overexpression. Targeting of YAP would be a reasonable approach, versus RSPO2‐driven HCC, to promote apoptosis of tumor cells. Verteporfin and statins are being tested as inhibitors of the Hippo pathway where verteporfin inhibits the Yap‐TEA domain transcription factor 1 (TEAD) interaction, whereas statins act by inhibition of ras homolog family member A (RhoA) signaling.[32](#hep41422-bib-0032){ref-type="ref"} Inhibiting YAP may selectively target HCC tumor cells that depend on it for survival. Porcupine inhibitors are candidate drugs to target RSPO‐high tumors.[33](#hep41422-bib-0033){ref-type="ref"}

Future studies are required to determine whether *RSPO*2 expression and downstream activation of canonical Wnt and Hippo pathways are required for tumor maintenance in *RSPO2‐*high cancers. Also unclear is the role of noncanonical Wnt signaling in RSPO2‐high cancers. In summary, we show that RSPO2 overexpression activates both canonical Wnt and Hippo signaling and promotes tumor formation in the liver. This raises the enticing possibility that both RSPOs and/or YAP could be used as biomarkers or therapeutic targets. Indeed, initial studies attempting therapeutic targeting of RSPOs are showing promise.[19](#hep41422-bib-0019){ref-type="ref"}, [21](#hep41422-bib-0021){ref-type="ref"} We have developed useful *in vitro* and *in vivo* model systems for the testing of targeting RSPOs or combination therapies with Wnt and/or Hippo/YAP inhibitors.
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